The 5 Most Interesting Analyst Questions From ResMed’s Q2 Earnings Call

ResMed (RMD) reported steady revenue growth but a decline in operating margin for its Q2 earnings, largely due to higher R&D and supply chain costs, and a $42 million charge for a field safety action. Analysts focused on gross margin drivers, revenue growth acceleration, acquisition strategy, the Astral field safety process, and the impact of GLP-1s on new patient acquisition. The company emphasized investments in innovation, cost discipline, and strategic tuck-in acquisitions, while noting GLP-1s as a tailwind for CPAP adoption despite initial adherence challenges.